Precigen (NASDAQ:PGEN) Announces Earnings Results, Beats Expectations By $0.01 EPS

Precigen (NASDAQ:PGEN) announced its earnings results on Wednesday. The biotechnology company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01, FiscalAI reports. Precigen had a negative net margin of 646.99% and a positive return on equity of 956.93%. The business had revenue of $23.25 million for the quarter, compared to the consensus estimate of $20.81 million.

Here are the key takeaways from Precigen’s conference call:

• PAPZIMEOS delivered a strong first full quarter of sales, with Q1 2026 net product revenue of $21.6 million versus $3.4 million in Q4 2025, and management said momentum is continuing into Q2.
• The company said launch adoption is broadening across major medical centers and community practices, with about 400 patients registered in the hub and roughly 25% coming from community settings.
• Precigen highlighted strong access dynamics, citing more than 90% of insured lives covered in the U.S. and the recent permanent J-code as factors that should simplify claims and support broader uptake.
• Financially, the quarter was better than the company’s prior launch phase, with operating loss of just $6 million and cash, cash equivalents and investments of $56.7 million; management reiterated it expects to reach cash flow break-even by the end of 2026 without needing to access capital markets.
• Beyond the commercial launch, Precigen said it plans to start a pediatric PAPZIMEOS trial in Q4 2026, expects EMA review to continue, and will provide ASCO durability data next month along with additional PRGN-2009 updates later this year.

Precigen Price Performance

NASDAQ PGEN traded down $0.17 on Friday, reaching $4.44. 2,598,249 shares of the company’s stock traded hands, compared to its average volume of 4,238,853. The stock has a market cap of $1.58 billion, a PE ratio of -3.76 and a beta of 1.07. Precigen has a 12 month low of $1.28 and a 12 month high of $5.47. The stock has a 50-day simple moving average of $3.83 and a 200 day simple moving average of $4.08. The company has a debt-to-equity ratio of 4.46, a current ratio of 3.09 and a quick ratio of 2.83.

Insider Buying and Selling at Precigen

In other news, Director Randal J. Kirk sold 4,772,781 shares of the company’s stock in a transaction on Monday, March 30th. The shares were sold at an average price of $3.30, for a total value of $15,750,177.30. Following the completion of the sale, the director owned 302,213 shares of the company’s stock, valued at approximately $997,302.90. This represents a 94.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 47.10% of the company’s stock.

Institutional Trading of Precigen

Hedge funds have recently added to or reduced their stakes in the business. Mason Investment Advisory Services Inc. purchased a new stake in Precigen during the fourth quarter valued at about $42,000. Abel Hall LLC bought a new stake in shares of Precigen in the 4th quarter valued at about $44,000. NewEdge Advisors LLC bought a new stake in shares of Precigen in the 4th quarter valued at about $45,000. Caitong International Asset Management Co. Ltd purchased a new stake in Precigen during the 3rd quarter valued at about $39,000. Finally, Cibc World Markets Corp purchased a new stake in Precigen during the 4th quarter valued at about $50,000. 33.51% of the stock is owned by institutional investors.

Precigen News Summary

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Precigen reported Q1 revenue of $23.25 million, beating estimates, and posted a smaller-than-expected loss per share, reinforcing investor confidence in the business update. Article Title
• Positive Sentiment: The company said PAPZIMEOS generated $21.6 million in net product revenue in Q1 2026, with management highlighting broad U.S. uptake and strong launch momentum, which is the main catalyst behind the stock’s rally. Article Title
• Positive Sentiment: Management said PAPZIMEOS could help fund operations to cash flow breakeven by the end of 2026, easing concerns about dilution or additional financing needs. Article Title
• Positive Sentiment: Citizens JMP raised its price target on Precigen to $11 from $9 and reiterated an outperform view, signaling growing Wall Street optimism after the earnings report. Article Title
• Neutral Sentiment: Analysts and commentary pieces are focusing on the company’s Q1 earnings call, upcoming ASCO durability data, and broader commercial validation of PAPZIMEOS, but these are more about future catalysts than immediate financial results. Article Title
• Neutral Sentiment: Coverage also referenced the stock’s sharp move and “massive rally,” but that reflects market reaction to the earnings and launch update rather than a new standalone negative or positive development. Article Title

Analysts Set New Price Targets

PGEN has been the topic of several research reports. HC Wainwright raised their price objective on shares of Precigen from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Thursday. Wall Street Zen upgraded shares of Precigen from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Citizens Jmp increased their target price on Precigen from $9.00 to $11.00 and gave the company a “market outperform” rating in a research note on Thursday. Citigroup restated an “outperform” rating on shares of Precigen in a research report on Thursday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precigen in a research note on Tuesday, April 21st. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Precigen has a consensus rating of “Hold” and an average price target of $11.00.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.